The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment

Diagnostic and Interventional Radiology

Volumn 16, Issue 3, 2010, Pages 186-192

  Türkbey, Bariş ^a   Thomasson, David ^b   Pang, Yuxi ^c   Bernardo, Marcelino ^a   Choyke, Peter L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c PHILIPS HEALTHCARE   (United States)

Author keywords

Angiogenic inhibitors; Magnetic resonance imaging; Pathologic angiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DENDRIMER; DEXTRAN; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE ALBUMIN; LIPOSOME;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; COLON CANCER; CONTRAST ENHANCEMENT; GYNECOLOGIC CANCER; HUMAN; IMAGE ANALYSIS; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; TUMOR VASCULARIZATION;

HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77957234029     PISSN: 13053825     EISSN: 13053612     Source Type: Journal    
DOI: 10.4261/1305-3825.DIR.2537-08.1     Document Type: Article

References (20)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
2. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2003; 17:509-520.
3. NCI, CIP guidelines: http://imaging.can-cer.gov/clinicaltrials/guideline.
4. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10:223-232.
5. De Lussanet QG, Langereis S, Beets-Tan RG, et al. Dynamic contrast-enhanced MR imaging: kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology 2005; 235:65-72.
6. Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 2005; 30:324-341.
7. Liu PF, Krestin GP, Huch RA, Göhde SC, Caduff RF, Debatin JF. MRI of the uterus, uterine cervix, and vagina: diagnostic performance of dynamic contrast-enhanced fast multiplanar gradient-echo imaging in comparison with fast spin-echo T2-weighted pulse imaging. Eur Radiol 1998; 8:1433-1440.
8. Jager GJ, Ruijter ET, van de Kaa CA, et al. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopatho-logic results. Radiology 1997; 203:645-652.
9. Ocak I, Bernardo M, Metzger G, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmaco-kinetic parameters. AJR Am J Roentgenol 2007; 189:849.
10. Barentsz JO, Berger-Hartog O, Witjes JA, et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 1998; 207:791-797.
11. Reddick WE, Taylor JS, Fletcher BD. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 1999; 10:277-285.
12. Devries AF, Griebel J, Kremser C, et al. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res 2001; 61:2513-2516.
13. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002; 15:154-163.
14. Mayr NA, Yuh WT, Arnholt JC, et al. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 2000; 12:1027-1033.
15. Thukral A, Thomasson DM, Chow CK, et al. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. Radiology 2007; 244:727-735.
16. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24:769-777.
17. Kosaka N, Uematsu H, Kimura H, et al. Assessment of the vascularity of uterine leiomyomas using double-echo dynamic perfusion-weighted MRI with the firstpass pharmacokinetic model: correlation with histopathology. Invest Radiol 2007; 42:629-635.
18. Hoskin PJ, Saunders MI, Goodchild K, Powell ME, Taylor NJ, Baddeley H. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol 1999; 72:1093-1098.
19. Taylor NJ, Lankester KJ, Stirling JJ, et al. Application, of navigator techniques to breath-hold DCE-MRI studies of the liver. In: Proceedings of the International Society of Magnetic Resonance in Medicine, 11th Scientific Meeting. Toronto, Canada, 2003, 1306.
20. Castro MA, Yao J, Turkbey B, Pang Y, Choyke PL, Thomasson D. Improvement of DCE-MR images to study liver cancer by means of a deformable registration algorithm. RSNA, Chicago, USA, 2008, 691.